With the outbreak of a new coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the public healthcare systems are facing great challenges. Coronavirus disease 2019 (COVID‐19) could develop into severe pneumonia, acute respiratory distress syndrome and multi‐organ failure. Remarkably, in addition to the respiratory symptoms, some COVID‐19 patients also suffer from cardiovascular injuries. Dipeptidyl peptidase‐4 (DPP‐4) is a ubiquitous glycoprotein which could act both as a cell membrane‐bound protein and a soluble enzymatic protein after cleavage and release into the circulation. Despite angiotensin‐converting enzyme 2 (ACE2), the recently recognized receptor of SARS‐CoV and SARS‐CoV‐2, which facilitated their entries into the host, DPP‐4 has been identified as the receptor of middle east respiratory syndrome coronavirus (MERS‐CoV). In the current review, we discussed the potential roles of DPP‐4 in COVID‐19 and the possible effects of DPP‐4 inhibitors on cardiovascular system in patients with COVID‐19.

中文翻译：

---

DPP-4抑制剂对COVID-19患者的心血管系统的潜在影响。

随着新的冠状病毒，严重的急性呼吸系统综合症冠状病毒2（SARS-CoV-2）的爆发，公共医疗系统面临着巨大的挑战。2019年冠状病毒病（COVID-19）可能发展为严重的肺炎，急性呼吸窘迫综合征和多器官衰竭。值得注意的是，除了呼吸道症状外，一些COVID-19病人还患有心血管损伤。Depteptidyl peptidase-4（DPP-4）是一种普遍存在的糖蛋白，在裂解并释放入循环后，既可以作为细胞膜结合蛋白，又可以作为可溶性酶蛋白。尽管有血管紧张素转换酶2（ACE2），但最近公认的SARS-CoV和SARS-CoV-2受体可以促进它们进入宿主，DPP-4已被确认为中东呼吸综合征冠状病毒（MERS-CoV）的受体。在当前的综述中，我们讨论了DPP-4在COVID-19中的潜在作用以及DPP-4抑制剂对COVID-19患者心血管系统的可能作用。